Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 |
| clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT01026142 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | completed | Phase 3 | 452 | Hoffmann-La RocheINDUSTRY | 23 | Aug 14, 2018 | clinicaltrials |
| NCT00552058 | Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | completed | Phase 3 | 439 | UCB PharmaINDUSTRY | 20 | Aug 9, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer(ZoptEC) | completed | Phase 3 | 511 | AEterna ZentarisINDUSTRY | 22 | Jul 31, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT03175341 | Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer | unknown | Phase 1 / Phase 2 | 30 | Academic Emergency County Hospital SibiuOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00552279 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age | completed | Phase 3 | 805 | GlaxoSmithKlineINDUSTRY | 3 | Jun 25, 2018 | clinicaltrials |
| NCT02557035 | An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting | completed | Phase 3 | 441 | Helsinn Healthcare SAINDUSTRY | 9 | Jun 20, 2018 | clinicaltrials |
| NCT01582061 | An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.(SEASCAPE) | completed | Phase 3 | 104 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 19, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT01262651 | Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer | completed | Phase 3 | 397 | GW Pharmaceuticals LtdINDUSTRY | 12 | Apr 23, 2018 | clinicaltrials |
| NCT00839332 | A Study for Participants With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | Eli Lilly and CompanyINDUSTRY | 6 | Apr 17, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly(PAOLA) | completed | Phase 3 | 198 | Novartis PharmaceuticalsINDUSTRY | 18 | Apr 5, 2018 | clinicaltrials |
| NCT00338286 | A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy | completed | Phase 3 | 2,098 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 19, 2018 | clinicaltrials |
| NCT01734967 | Needle-based Confocal Endomicroscopy Examination of Pancreatic Masse | completed | N/A | 28 | Herlev HospitalOTHER | 2 | Feb 23, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT02459041 | Clinical Impact of EUS Elastography Mean Strain Histograms (SH) and Contrast Peak-enhancement in Focal Pancreatic Masses and Lymph Nodes(ADVEUS) | completed | — | 100 | University of Medicine and Pharmacy CraiovaOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT02494388 | Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions(CINE-Cyst) | terminated | — | 10 | University of Medicine and Pharmacy CraiovaOTHER | 4 | Jan 17, 2018 | clinicaltrials |
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 731 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT00040183 | OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. | completed | Phase 3 | 569 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT00911170 | PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study | completed | Phase 3 | 847 | AmgenINDUSTRY | 17 | Dec 29, 2017 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT01187381 | An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(HERODOT) | terminated | — | 250 | Hoffmann-La RocheINDUSTRY | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01265901 | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 3 | 339 | Immatics Biotechnologies GmbHINDUSTRY | 11 | Oct 12, 2017 | clinicaltrials |
| NCT00943826 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | completed | Phase 3 | 921 | Hoffmann-La RocheINDUSTRY | 24 | Sep 25, 2017 | clinicaltrials |
| NCT00711958 | Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients | completed | Phase 3 | 114 | SandozINDUSTRY | 2 | Sep 5, 2017 | clinicaltrials |
| NCT00431236 | A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | completed | Phase 3 | 810 | GlaxoSmithKlineINDUSTRY | 22 | Aug 22, 2017 | clinicaltrials |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | completed | Phase 4 | 545 | Hoffmann-La RocheINDUSTRY | 24 | Aug 14, 2017 | clinicaltrials |
| NCT01735175 | Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®(PROTECT-1) | completed | Phase 3 | 316 | SandozINDUSTRY | 6 | Aug 7, 2017 | clinicaltrials |
| NCT03237884 | Romanian-Swiss Research Programme IZERZO(IZERZO) | completed | — | 308 | Cantonal Hospital of St. GallenOTHER | 2 | Aug 3, 2017 | clinicaltrials |
| NCT00090051 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | completed | Phase 3 | 552 | Hoffmann-La RocheINDUSTRY | 17 | Aug 1, 2017 | clinicaltrials |
| NCT02300831 | LUMINIST: LUng Cancer Molecular Insights Non Interventional Study(LUMINIST) | completed | — | 770 | AstraZenecaINDUSTRY | 23 | Jul 14, 2017 | clinicaltrials |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,560 | Millennium Pharmaceuticals, Inc.INDUSTRY | 40 | May 17, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer(SUNRISE) | completed | Phase 3 | 582 | Peregrine PharmaceuticalsINDUSTRY | 14 | Apr 21, 2017 | clinicaltrials |
| NCT01308580 | Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer(PROSELICA) | completed | Phase 3 | 1,200 | SanofiINDUSTRY | 22 | Apr 17, 2017 | clinicaltrials |
| NCT01153984 | A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations(BIOTEC) | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01217697 | Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer | approved for marketing | — | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 24 | Mar 24, 2017 | clinicaltrials |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 183 | GlaxoSmithKlineINDUSTRY | 19 | Mar 23, 2017 | clinicaltrials |
| NCT01444456 | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia | completed | — | 1,262 | AmgenINDUSTRY | 9 | Mar 20, 2017 | clinicaltrials |
| NCT01412957 | Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 377 | AmgenINDUSTRY | 16 | Mar 15, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials